Drugs / GL101
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02656394 Comparator | Jan 2016 → Dec 2017 | eye adnexa disorder | Glia, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GL101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02656394 ↗ |
| Route | Topical | “0.5% GL101 topical gel administered twice daily for 28 days” NCT02656394 ↗ |